Journal
PHARMACOGENOMICS JOURNAL
Volume 11, Issue 4, Pages 287-291Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2010.32
Keywords
methotrexate; transaminases; pharmacogenetics; rheumatoid arthritis; MTHFR
Categories
Funding
- Fondo para el Fomento de la Investigacion Medica (FOFOI)
- Instituto Mexicano del Seguro Social
- Consejo Nacional de Ciencia y Tecnologia, Mexico (CONACYT)
- CUCS, Universidad de Guadalajara, Jal. Mexico
- [IMSS-2002/252/037]
Ask authors/readers for more resources
Rheumatoid arthritis (RA) is the prototype of the rheumatic diseases worldwide. Methotrexate (MTX) is the drug of first choice in the treatment of this disease due to its immunosuppressant effect. However, side events are present in 30% of the patients. The C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene are involved in the metabolism of MTX. Earlier studies reported an association between these polymorphisms and elevation of hepatic enzymes. We analyzed the frequencies of both polymorphisms and the presence of transaminasemia in 70 Mexican patients with rheumatic arthritis treated with MTX. The 19% (13/70) of patients had an increase in the serum level of transaminases. The A1298C polymorphism was associated with elevation of transaminases (P = 0.024). The identification of MTHFR genotypes for C677T and A1298C polymorphisms could lead clinicians to identify patients in risk of elevation of transaminases, and give them an individualized treatment, as is a goal of pharmacogenetics. The Pharmacogenomics Journal (2011) 11, 287-291; doi:10.1038/tpj.2010.32; published online 1 June 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available